Previous close | 0.1715 |
Open | 0.1889 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 900 |
Day's range | 0.1720 - 0.1889 |
52-week range | 0.1000 - 0.6240 |
Volume | |
Avg. volume | 4,190,603 |
Market cap | 21.623M |
Beta (5Y monthly) | 2.14 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.3120 |
Earnings date | 06 Mar 2023 - 10 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 3.00 |
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -16.67% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.